Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
58
LMAT Quote, Financials, Valuation and Earnings
Last price:
$92.19
Seasonality move
:
2.06%
Day range:
$90.61 - $93.60
52-week range:
$52.88 - $109.58
Dividend yield:
0.7%
P/E ratio:
50.34x
P/S ratio:
9.79x
P/B ratio:
6.26x
Volume:
435.2K
Avg. volume:
180.3K
1-year change:
67.97%
Market cap:
$2.1B
Revenue:
$193.5M
EPS (TTM):
$1.83
Analysts' Opinion
-
Consensus RatingLeMaitre Vascular has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $98.78, LeMaitre Vascular has an estimated upside of 7.22% from its current price of $92.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $85.00 representing 7.74% downside risk from its current price of $92.13.
Fair Value
-
According to the consensus of 7 analysts, LeMaitre Vascular has 7.22% upside to fair value with a price target of $98.78 per share.
LMAT vs. S&P 500
-
Over the past 5 trading days, LeMaitre Vascular has underperformed the S&P 500 by -6.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
LeMaitre Vascular does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
LeMaitre Vascular has grown year-over-year revenues for 17 quarters straight. In the most recent quarter LeMaitre Vascular reported revenues of $54.8M.
Earnings Growth
-
LeMaitre Vascular has grown year-over-year earnings for 6 quarters straight. In the most recent quarter LeMaitre Vascular reported earnings per share of $0.49.
Enterprise value:
1.9B
EV / Invested capital:
5.88x
Price / LTM sales:
9.79x
EV / EBIT:
37.54x
EV / Revenue:
9.14x
PEG ratio (5yr expected):
0.98x
EV / Free cash flow:
58.15x
Price / Operating cash flow:
62.30x
Enterprise value / EBITDA:
31.66x
Gross Profit (TTM):
$145.6M
Return On Assets:
11.64%
Net Income Margin (TTM):
19.4%
Return On Equity:
13.37%
Return On Invested Capital:
13.37%
Operating Margin:
23.98%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $160.2M | $185.6M | $213M | $47.4M | $54.8M | |
| Gross Profit | $104.8M | $119.8M | $145.6M | $30.8M | $37.2M | |
| Operating Income | $31.3M | $34M | $49.6M | $9.2M | $13.1M | |
| EBITDA | $41.4M | $40.9M | $61.5M | $11.6M | $15.6M | |
| Diluted EPS | $0.96 | $1.21 | $1.83 | $0.33 | $0.49 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $102.3M | $134M | $153.1M | $182.2M | $227.1M | |
| Total Assets | $261.6M | $289.5M | $302M | $334M | $377M | |
| Current Liabilities | $44.4M | $22.1M | $23.4M | $29M | $29.3M | |
| Total Liabilities | $100.6M | $40.4M | $40.8M | $45.4M | $46M | |
| Total Equity | $161M | $249M | $261.2M | $288.6M | $331.1M | |
| Total Debt | $59.5M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $26.4M | $30.1M | $39.7M | $11.8M | $14.2M | |
| Cash From Investing | -$17.2M | -$22.9M | -$28.5M | -$9.9M | -$12.9M | |
| Cash From Financing | -$8.3M | -$6.6M | -$8.7M | -$3.1M | -$3.1M | |
| Free Cash Flow | $23.8M | $22.8M | $33.5M | $10.8M | $12.6M | |
LMAT
Sector
Market Cap
$2.1B
$43.9M
Price % of 52-Week High
84.08%
45.73%
Dividend Yield
0.7%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
67.97%
-29.11%
Beta (5-Year)
0.933
0.772
Dividend yield:
0.7%
Annualized payout:
$0.56
Payout ratio:
33.63%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$94.95
200-day SMA
Buy
Level
$83.75
Bollinger Bands (100)
Sell
Level
85.3 - 99.88
Chaikin Money Flow
Buy
Level
22.4M
20-day SMA
Sell
Level
$100.43
Relative Strength Index (RSI14)
Sell
Level
36.22
ADX Line
Buy
Level
4.35
Williams %R
Neutral
Level
-79.4489
50-day SMA
Sell
Level
$97.44
MACD (12, 26)
Sell
Level
-2.14
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
19.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (17.5262)
Buy
CA Score
(Annual)
Level (1.9662)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-3.9437)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Stock Forecast FAQ
In the current month, LMAT has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The LMAT average analyst price target in the past 3 months is $98.78.
-
Where Will LeMaitre Vascular Stock Be In 1 Year?
According to analysts, the consensus estimate is that LeMaitre Vascular share price will rise to $98.78 per share over the next 12 months.
-
What Do Analysts Say About LeMaitre Vascular?
Analysts are divided on their view about LeMaitre Vascular share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LeMaitre Vascular is a Sell and believe this share price will drop from its current level to $85.00.
-
What Is LeMaitre Vascular's Price Target?
The price target for LeMaitre Vascular over the next 1-year time period is forecast to be $98.78 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is LMAT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for LeMaitre Vascular is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LMAT?
You can purchase shares of LeMaitre Vascular via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LeMaitre Vascular shares.
-
What Is The LeMaitre Vascular Share Price Today?
LeMaitre Vascular was last trading at $92.19 per share. This represents the most recent stock quote for LeMaitre Vascular. Yesterday, LeMaitre Vascular closed at $92.13 per share.
-
How To Buy LeMaitre Vascular Stock Online?
In order to purchase LeMaitre Vascular stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 7.8% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 11.48% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 2.74% over the past day.
